ARBORXR
25.5.2022 19:39:05 CEST | Business Wire | Press release
ArborXR announced today the company will work with Qualcomm Technologies, Inc. on an extended reality (XR) mobile device management (MDM) platform to make it easier for companies to scale virtual reality (VR) and augmented (AR) headset deployments.
By working closely with original equipment manufacturer (OEM) partners and direct enterprise clients, ArborXR and Qualcomm Technologies have identified key problems that still exist in scaling a fleet of XR headsets. Companies today looking to deploy a fleet of VR or AR devices face many challenges enrolling and provisioning headsets, managing them remotely, installing apps and updates, and controlling the user experience.
To solve these problems, ArborXR will provide device management software to Qualcomm Technologies’ XR customers and OEMs with large-scale deployments for use with Qualcomm Technologies’ cutting edge VR/AR hardware available. OEMs will be able to pre-install ArborXR, and ArborXR’s software will support new VR and AR reference designs from Qualcomm Technologies early in the development cycle.
ArborXR’s software allows organizations to manage VR & AR devices, deploy apps remotely, and lock down the user experience with a kiosk mode and a customizable launcher. Current ArborXR customers include Fortune 500 companies, universities and hundreds of independent software vendors.
“With large scale deployments, we’ve increasingly seen a need for this kind of deeper integration,” said ArborXR CEO Brad Scoggin. “By working with Qualcomm Technologies at the Snapdragon® platform level and directly with OEMs, we will be able to provide companies a powerful and seamless platform for managing their fleets.”
“We recognize the friction that still exists in deploying large numbers of VR & AR devices. Working with ArborXR can help us solve this problem,” said Said Bakadir, senior director of XR product management, Qualcomm Technologies, Inc. “We are confident this collaboration with ArborXR will result in tremendous benefits for our customers and partners as we support their efforts to manage large-scale deployments.”
Companies can get started using ArborXR for free on up to 50 devices. To learn more, visit ArborXR.com .
About ArborXR
ArborXR puts you in command of XR device management. Confidently manage VR & AR devices at scale, remotely deploy content, and control what users can see and do. ArborXR is built with enterprise-level security and through working closely with dozens of Fortune 500 companies. Our mission is to help people live more meaningful lives through the power of XR. Join more than 600 companies in 60 countries already using ArborXR to manage their AR and VR fleets and learn more at ArborXR.com .
Snapdragon is a product of Qualcomm Technologies, Inc. and/or its subsidiaries. Snapdragon is a trademark or registered trademark of Qualcomm Incorporated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005865/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to DB Insurance9.2.2026 15:26:00 CET | Press release
Align Partners underscores DBI’s persistent undervaluation (0.40x Adjusted PBR), despite industry-leading profitability, identifying inefficient capital allocation and governance issues as primary driversAlign Partners outlines measures for capital efficiency and governance normalization; requests a revised “Value-up” plan and a formal response from the Board by March 6, 2026The proposals nominate two Independent Directors via separate election and calls for the reinstatement of the Internal Transaction Committee Align Partners Capital Management Inc. (“Align Partners”), a shareholder of DB Insurance Co., Ltd. (KRX:005830) (“DBI” or the “Company”) holding 1.9%, has issued a public shareholder letter to DBI’s Board of Directors aimed at strengthening capital allocation policy and governance oversight, and submitted formal shareholder proposals for the 2026 Annual General Meeting (“AGM”). Despite DBI’s robust fundamentals—including a 16.1% ROE and a 226% K-ICS ratio—the Company trades at
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 13:00:00 CET | Press release
TarSeer™ BRETSA™ Target Engagement System enables studies for difficult proteins early in drug discovery Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/
Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 13:00:00 CET | Press release
Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V
HKTDC to Host World’s Largest One-Stop Jewellery Marketplace9.2.2026 11:37:00 CET | Press release
New Hard Pure Gold Pavilion showcases breakthrough gold technologies Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one‑stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld‑Expo, featuring a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre, showcasing finished jewellery pieces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207153040/en/ Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with nearly 70% coming
FlexTrade Integrates CME Group’s FX Spot+ and EBS Market Offerings for Enhanced FX Trading9.2.2026 11:30:00 CET | Press release
The initiative will see FlexTrade FX clients seamlessly access CME Group’s primary FX markets within FlexFX. FlexTrade Systems(@FlexTrade), a global leader in multi-asset execution and order management systems, today announced an integration with CME Group’s EBS Market central limit order book (CLOB) and its FX Spot+ platform.The move is designed to diversify and deepen the sources of actionable liquidity available to FlexTrade’s FlexFX users through an integration into CME Group's substantial liquidity pools for spots via FX Spot+. Providing firm, anonymous liquidity and no last-look pricing, EBS Market is a venue for both large market participants in search of FX liquidity in an all-to-all CLOB, and for market-making banks hedging FX risk. FX Spot+ further enhances spot liquidity with Futures liquidity from CME Group. This partnership is integral in helping firms further expand FX liquidity and take advantage of global opportunity. Mutual clients of FlexTrade and CME Group can integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom